Bionano Genomics Inc logo

BNGO - Bionano Genomics Inc Share Price

$9.73 -0.3  -2.9%

Last Trade - 26/02/21

Market Cap £1.27bn
Enterprise Value £1.27bn
Revenue £5.24m
Position in Universe 2280th / 6715
Unlock BNGO Revenue
Relative Strength (%)
1m -12.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 6.79 9.51 12.0 10.1 8.01 18.4 +14.2%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, BioNanoGenomics Inc revenues decreased 39% to $4.5M. Net lossincreased 34% to $29.4M. Revenues reflect Northern Americasegment decrease of 41% to $2.4M, Asia Pacific segmentdecrease of 76% to $217K. Higher net loss reflects Selling,general and administrative - Ba increase of 54% to $20.8M(expense), Research and development - Balancing valincrease of 9% to $7.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BNGO
Graphical History


BNGO Revenue Unlock BNGO Revenue

Net Income

BNGO Net Income Unlock BNGO Revenue

Normalised EPS

BNGO Normalised EPS Unlock BNGO Revenue

PE Ratio Range

BNGO PE Ratio Range Unlock BNGO Revenue

Dividend Yield Range

BNGO Dividend Yield Range Unlock BNGO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BNGO EPS Forecasts Unlock BNGO Revenue
Profile Summary

Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 24, 2003
Public Since August 1, 2018
No. of Shareholders: 90
No. of Employees: 97
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 181,680,905
Free Float (0.0%)
Eligible for
BNGO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BNGO
Upcoming Events for BNGO
Frequently Asked Questions for Bionano Genomics Inc
What is the Bionano Genomics Inc share price?

As of 26/02/21, shares in Bionano Genomics Inc are trading at $9.73, giving the company a market capitalisation of £1.27bn. This share price information is delayed by 15 minutes.

How has the Bionano Genomics Inc share price performed this year?

Shares in Bionano Genomics Inc are currently trading at $9.73 and the price has moved by 0.924k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bionano Genomics Inc price has moved by 0.690k% over the past year.

What are the analyst and broker recommendations for Bionano Genomics Inc?

Of the analysts with advisory recommendations for Bionano Genomics Inc, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bionano Genomics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Bionano Genomics Inc next release its financial results?

Bionano Genomics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Bionano Genomics Inc dividend yield?

Bionano Genomics Inc does not currently pay a dividend.

Does Bionano Genomics Inc pay a dividend?

Bionano Genomics Inc does not currently pay a dividend.

When does Bionano Genomics Inc next pay dividends?

Bionano Genomics Inc does not currently pay a dividend.

How do I buy Bionano Genomics Inc shares?

To buy shares in Bionano Genomics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bionano Genomics Inc?

Shares in Bionano Genomics Inc are currently trading at $9.73, giving the company a market capitalisation of £1.27bn.

Where are Bionano Genomics Inc shares listed? Where are Bionano Genomics Inc shares listed?

Here are the trading details for Bionano Genomics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BNGO
What kind of share is Bionano Genomics Inc?

Based on an overall assessment of its quality, value and momentum, Bionano Genomics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bionano Genomics Inc share price forecast 2021?

Shares in Bionano Genomics Inc are currently priced at $9.73. At that level they are trading at 12.44% discount to the analyst consensus target price of 0.00.

Analysts covering Bionano Genomics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.4 for the next financial year.

How can I tell whether the Bionano Genomics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionano Genomics Inc. Over the past six months, the relative strength of its shares against the market has been 1.33k%. At the current price of $9.73, shares in Bionano Genomics Inc are trading at 0.310k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bionano Genomics Inc PE Ratio?

We were not able to find PE ratio data for Bionano Genomics Inc.

Who are the key directors of Bionano Genomics Inc?

Bionano Genomics Inc's management team is headed by:

R. Erik Holmlin - PRE
Mark Oldakowski - COO
David Barker - CHM
Albert Luderer - IND
Christopher Twomey - IND
Kristiina Vuori - IND
Hannah Mamuszka - DRC
Yvonne Linney - DRC
Alka Chaubey - OTH
Christopher Stewart - CFO
Who are the major shareholders of Bionano Genomics Inc?

Here are the top five shareholders of Bionano Genomics Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.93% (7.13m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.72% (4.95m shares)
Vanguard Extended Market Index Fund Mutual Fund
Percentage owned: 1.44% (2.62m shares)
Pura Vida Investments, LLC Hedge Fund
Percentage owned: 1.16% (2.10m shares)
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund
Percentage owned: 0.52% (945k shares)
Similar to BNGO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.